申请人:Rajagopalan Raghavan
公开号:US20060100282A1
公开(公告)日:2006-05-11
This invention relates to novel diaminopropane-based divalent metal ion chelating ligands of Formula I,
wherein A is selected from the group consisting of —(CH
2
)
a
—, —(CH
2
)
b
O(CH
2
)
c
—, —(CH
2
O)
d
—, and —(CH
2
)
e
N(R
4
)(CH
2
)
f
—; a and c vary from 0 to 10; b, e, and f vary from 2 to 10, and d varies from 1 to 10. X and Y are independently —CR
5
R
6
, or —CH(R
7
)CH(R
8
). R
1
to R
8
are various substituents selected to optimize the physicochemical and biological properties such as enzyme binding, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 13. R
1
to R
8
may include, but are not limited to hydrogen, alkyl, acyl, hydroxyl, hydroxyalkyl, substituted or unsubstituted aryl, amino, aminoalkyl, alkoxyl, aryloxyl, carboxyl, halogen, alkoxycarbonyl, cyano, and other suitable electron donating or electron withdrawing groups. Ar may unsubstituted phenyl group or may be substituted with suitable electron donating or electron withdrawing groups. The compounds of the present invention are useful for inhibiting the activity of viral enzymes responsible for the proliferation of human immunodeficiency virus (HIV).
这项发明涉及一种新型的二胺丙烷基二价金属离子螯合配体,其化学式为I,其中A从以下组中选择:—(CH2)a—、—(CH2)bO(CH2)c—、—(CH2O)d—和—(CH2)eN(R4)(CH2)f—;a和c的取值范围为0至10;b、e和f的取值范围为2至10;d的取值范围为1至10。X和Y独立地为—CR5R6或—CH(R7)CH(R8)。R1至R8是各种取代基,用于优化化合物的物理化学和生物学性质,如酶结合、组织渗透性、亲脂性、毒性、生物利用度和药代动力学。R1至R8可能包括但不限于氢、烷基、酰基、羟基、羟基烷基、取代或未取代芳基、氨基、氨基烷基、烷氧基、芳氧基、羧基、卤素、烷氧羰基、氰基和其他适当的电子给体或电子抽提基团。Ar可能是未取代的苯基或含有适当的电子给体或电子抽提基团的取代苯基。本发明的化合物可用于抑制负责人类免疫缺陷病毒(HIV)增殖的病毒酶的活性。